Norfenefrine in the Treatment of Female Stress Incontinence: A Double-Blind Controlled Trial

Lose, Gunnar; Rix, Per; Diernoes, E.; Alexander, Niels

doi:10.1016/s0022-5347(17)41386-3

Cited by 6 publications

(11 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Neither elevation of blood pressure nor deteriorating effects on liver function, hematopoietic system and renal function was observed in spite of the maintenance of 90 mg NF daily during 6 months. This low incidence of side effects is in accordance with previous reports [11,12,25] and we suggest that NF is a safe drug to use when a-agonist treatment of female SI is considered.…”

Section: Discussionsupporting

confidence: 93%

“…When comparing the results of this study with the placebo-controlled study of Lose et al [ 12], we found the overall effect on the symptom SI to be the same (about 50%). Despite considerable leakage, however, a significant effect of NF could be demonstrated when the effect was measured by OPT.…”

Section: Discussionsupporting

confidence: 60%

“…Despite considerable leakage, however, a significant effect of NF could be demonstrated when the effect was measured by OPT. Lose et al [ 12] also found a significant effect of NF compared to placebo in the reduced use of pants and pads. Furthermore, a subgroup analysis indicated a significant effect of NF in patients with most severe incontinence.…”

Section: Discussionmentioning

confidence: 92%

“…We have studied the effects of the a-adrenergic ago nist norfenefrine (NF) for some years in patients with SI, using symptom score, stress test and urodynamics as parameters [11,12]. However, in 1982 the use of a 1-hour pad test (OPT) was recommended as the optimal test for quantifying urine loss [13].…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Norfenefrine in the Treatment of Female Urinary Stress Incontinence Assessed by One-Hour Pad Weighing Test

Diernaes

Rix²,

Sørensen³

et al. 1989

Urol Int

View full text Add to dashboard Cite

Thirty-three women with urinary stress incontinence were treated with the Α-adrenoceptor-stimulating agent, norfenefrine (Nevadral Retard). Treatment was administered during 3–24 weeks at a daily dosage of 90 mg. Judged by a 1-hour pad weighing test, a significant effect could be demonstrated. With the exception of 1 case of allergic reaction and 1 case of recurrent vomiting, a simultaneously performed tolerability test revealed only minor side effects.

show abstract

Section: Discussionsupporting

confidence: 93%

Section: Discussionsupporting

confidence: 60%

Section: Discussionmentioning

confidence: 92%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Norfenefrine in the Treatment of Female Urinary Stress Incontinence Assessed by One-Hour Pad Weighing Test

Diernaes

Rix²,

Sørensen³

et al. 1989

Urol Int

View full text Add to dashboard Cite

show abstract

“…Eleven patients received placebo only, 13 received norfenefrine only, 10 were crossed from placebo to norfenefrine and 10 patients were crossed from norfenefrine to placebo. The results of this trial have been described elsewhere [10].…”

Section: Methodsmentioning

confidence: 99%

Does Medical Therapy Cure Female Stress Incontinence?

Lose

Diernaes²,

Rix³

1989

Urol Int

Self Cite

View full text Add to dashboard Cite

Forty-four consecutive female patients, who were scheduled for operation for genuine stress incontinence but instead treated pharmacologically with an Α-agonist or placebo for 3–4.5 months, were evaluated after a median observation period of 30 months. Ten patients (23%) underwent colposuspension. Fourteen patients (32%) claimed to be continent or so much improved that further treatment was considered unnecessary by the patients themselves. Of the remaining 20 patients who still claimed to have stress incontinence, 11 (25%) preferred to resume the pharmacological treatment whereas 9 patients (20%) had not decided whether they wanted further treatment. These results suggest that some operations for stress incontinence may be avoided by introduction of a standard trial of medical therapy prior to intended surgical intervention.

show abstract

Le traitement conservateur de l’incontinence urinaire d’effort de la femme

Denys

Kerdraon

2010

Pelv Perineol

View full text Add to dashboard Cite

But : Regrouper des niveaux de preuve et/ou des grades de recommandation issus d'une revue de la littérature relative aux traitements non chirurgicaux de l'incontinence urinaire chez la femme. Matériel et méthodes : Revue systématique par recherche numérique dans Medline, Cinahh, Cochrane Library, National Library for Health (NLH), en appliquant lorsque possible des niveaux de preuve et/ou de grades de recommandations selon les critères énoncés par la HAS. Résultats : Soixante-douze études contrôlées randomisées et huit revues de la Cochrane Library ont été identifiées dans le champ des traitements conservateurs de l'incontinence urinaire chez la femme. Conclusion : Il existe des niveaux de preuve pour établir que le renforcement musculaire du plancher périnéal et les programmes de rééducation comportementale peuvent guérir l'incontinence urinaire chez la femme. En cas de surpoids, la perte de poids améliore l'incontinence urinaire. La duloxétine améliore l'incontinence et la qualité de vie, mais sa place n'est actuellement pas déterminée dans l'algorithme des traitements conservateurs. Les effets de l'électrostimula-tion périnéale et de l'estrogénothérapie sont inconstants ou inhomogènes.Mots clés Incontinence urinaire · Femme · Traitement conservateur · Niveau de preuve Abstract Objectives: To synthetize evidence-based results related to nonsurgical management for urinary incontinence in women. Materials and methods: Electronic search in Pubmed, Cinahl, Cochrane Library, and National Library for Health. Results: There were 72 randomized control studies and eight review from the Cochrane Library. Conclusion: Moderate to high levels of evidence suggest that weight loss from obesity state, pelvic muscle training, and bladder training may resolve urinary incontinence in women. The effects of electrical stimulation of pelvic floor, oestrogene therapy were inconstant or inhomogeneous. Duloxetine may improve continence and quality of life, but its range in therapeutic algorithm is still to be defined.

show abstract

Norfenefrine in the Treatment of Female Stress Incontinence: A Double-Blind Controlled Trial

Cited by 6 publications

References 0 publications

Norfenefrine in the Treatment of Female Urinary Stress Incontinence Assessed by One-Hour Pad Weighing Test

Norfenefrine in the Treatment of Female Urinary Stress Incontinence Assessed by One-Hour Pad Weighing Test

Does Medical Therapy Cure Female Stress Incontinence?

Le traitement conservateur de l’incontinence urinaire d’effort de la femme

Contact Info

Product

Resources

About